Search
Regulatory Story
Company Clinigen Group plc
TIDM CLIN
Headline Notification of half year results date
Released 07:00 12-Feb-2019
Number 6853P07

RNS Number : 6853P
Clinigen Group plc
12 February 2019
 

12 February 2019

 

Notification of half year results date

 

 

Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the global pharmaceutical and services company, will announce its half year results for the six months ended 31 December 2018 on Wednesday, 27 February 2019.

 

A group analyst briefing will be held at 9:30am on Wednesday, 27 February 2019 at Instinctif Partners' offices at 65 Gresham Street, London EC2V 7NQ.

 

Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email clinigen@instinctif.com to register.

 

-Ends-

 

Contact Details

 

Clinigen Group plc

Tel: +44 (0) 1283 495 010

Shaun Chilton, Group Chief Executive Officer

 

Martin Abell, Group Chief Financial Officer

 

Matt Parrish, Head of Investor Relations

 

 

 

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

 

James Black / Tom Ballard (Corporate Broking)

 

 

 

RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas

 

 

 

Instinctif Partners (media relations)

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Alex Shaw

Email: clinigen@instinctif.com

 

Notes to Editors

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific. In October 2018, the Group acquired CSM, a specialist provider of packaging, labelling, warehousing and distribution services, with sites in the US and Europe, and iQone, as specialist pharmaceutical company in Switzerland.  For more information, please visit the website at www.clinigengroup.com.

 

For more information, please visit www.clinigengroup.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBLGDDGUBBGCB
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.